Bourgeon Capital Management LLC Maintains Position in Achillion Pharmaceuticals, Inc. (ACHN)
Bourgeon Capital Management LLC continued to hold its stake in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) during the second quarter, Holdings Channel reports. The firm owned 34,500 shares of the biopharmaceutical company’s stock at the end of the second quarter. Bourgeon Capital Management LLC’s holdings in Achillion Pharmaceuticals were worth $158,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently bought and sold shares of ACHN. Deschutes Portfolio Strategy LLC boosted its stake in Achillion Pharmaceuticals by 13.4% in the first quarter. Deschutes Portfolio Strategy LLC now owns 25,430 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 3,000 shares in the last quarter. Teza Capital Management LLC bought a new position in shares of Achillion Pharmaceuticals during the first quarter worth approximately $131,000. TradeLink Capital LLC bought a new position in shares of Achillion Pharmaceuticals during the second quarter worth approximately $132,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Achillion Pharmaceuticals during the first quarter worth approximately $138,000. Finally, Highbridge Capital Management LLC bought a new position in shares of Achillion Pharmaceuticals during the first quarter worth approximately $149,000. Institutional investors and hedge funds own 70.83% of the company’s stock.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) opened at 4.695 on Friday. The company’s market cap is $642.09 million. The stock has a 50 day moving average of $4.39 and a 200-day moving average of $4.13. Achillion Pharmaceuticals, Inc. has a one year low of $3.15 and a one year high of $9.49.
Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, hitting the consensus estimate of ($0.16). During the same quarter in the prior year, the firm posted ($0.14) earnings per share. On average, equities analysts predict that Achillion Pharmaceuticals, Inc. will post ($0.63) EPS for the current fiscal year.
A number of brokerages have recently commented on ACHN. Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday. Robert W. Baird lowered shares of Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price target on the stock. in a report on Thursday. Maxim Group set a $7.00 price target on shares of Achillion Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday. Chardan Capital decreased their price target on shares of Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating on the stock in a report on Wednesday. Finally, BidaskClub lowered shares of Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, August 5th. Two analysts have rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $8.25.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.